This guidance emphasizes the critical need for healthcare professionals to differentiate between types of angioedema associated with ACE inhibitors, which could significantly influence treatment approaches and patient outcomes. Pharma companies must adapt their educational resources to align with these clinical distinctions to ensure patient safety and support prescriber confidence. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 10 ranked evidence items (3 high-relevance).